---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-062027"
form_type: "8-K"
ticker: "BOLT"
cik: "0001641281"
company_name: "Bolt Biotherapeutics, Inc."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T06:50:28.482724+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Bolt Biotherapeutics Q3 2023: cash $141.4M, BDC-1001 29% ORR, BDC-3042 dosed

## Summary
- Cash, cash equivalents and marketable securities of $141.4M as of Sept 30, 2023; expected to fund operations through 2025.
- Collaboration revenue $2.5M (vs $2.1M Q3 2022); R&D expenses $15.0M (down from $19.0M).
- Loss from operations of $18.2M vs $22.3M in prior year quarter.
- BDC-1001 Phase 1 updated data: 29% ORR monotherapy; first complete response; well tolerated; Orphan Drug Designation for gastric cancers.
- First patient dosed with BDC-3042 in Phase 1/2 for advanced solid tumors.

## SEC filing metadata
- accession: 0000950170-23-062027
- form_type: 8-K
- ticker: BOLT
- cik: 0001641281
- company_name: Bolt Biotherapeutics, Inc.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1641281/000095017023062027/0000950170-23-062027-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1641281/000095017023062027/bolt-20231109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-062027
- JSON: https://secwatch.observer/filing/0000950170-23-062027.json
- Plain text: https://secwatch.observer/filing/0000950170-23-062027.txt

## Key facts
- Earnings Releases
  Bolt Biotherapeutics, Inc. reported the third quarter ended September 30, 2023 results: revenue $2.5 million.
  - Period: the third quarter ended September 30, 2023
  - Revenue: $2.5 million
  - Result: reported results
  source text: 2023. Cash on hand is expected to fund multiple milestones and operations through 2025. Third Quarter 2023 Financial Results • Collaboration Revenue – Collaboration revenue was $2.5 million for the quarter ended September 30, 2023, compared to $2.1 million for the same quarter in 2022. Revenue in the comparative periods were generated from the services performed
  evidence_url: https://www.sec.gov/Archives/edgar/data/1641281/000095017023062027/0000950170-23-062027-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.